Rare disease
Platform
Oligonucleotides Intron-targeting RNA therapeutics
Our innovative oligonucleotide approach provides high potency, can be tailored for allele-specific applications, and minimizes the off-target effects commonly associated with other RNA-based therapies.
Poul Sørensen, Partner and Entrepreneur in Residence at Argobio, has extensive leadership experience in R&D and corporate development from top tier international Biotech and Pharmaceutical companies (Pharmacia, LEO Pharma, Micromet, ALK-Abello, Stallergenes Greer) across multiple indications within immuno-oncology, inflammation, neurology and immune disorders. He brings to ArgoBio studio more than 25 years’ experience and passion for translating ground-breaking innovation into therapeutics and new product developments, strategic co-operations and creation of new ventures. As a serial biotech entrepreneur Poul has co-founded several start-ups including Allero Therapeutics as CSO.
Poul holds a PhD in Biochemistry from Copenhagen University and is Honorary Professor in Biomedicine at Aarhus University in Denmark.